MA1-19342

antibody from Invitrogen Antibodies

Targeting: AFP FETA, HPAFP

Western blot (Supportive data in Antibodypedia)

ELISA (Recommended by provider)

Immunohistochemistry (Supportive data in Antibodypedia)

Radioimmunoassay (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-19342

Provider

Invitrogen Antibodies

Product name

AFP Monoclonal Antibody (AFP-11)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

This antibody reacts with human alpha-Fetoprotein (AFP), a 70 kDa oncofetal antigen. AFP is a major fetal plasma protein, but is not present in healthy adult tissues. Elevated AFP concentrations in adult plasma may be an early marker of hepatocellular carcinoma or teratoblastoma, while high concentrations in amniotic fluid may indicate severe congenital defects of a fetus. The MA1-19342 anti-alpha Fetoprotein antibody (clone AFP-11) has successfully been paired as the coating antibody in a sandwich ELISA with detection antibody MA1-19178 (clone AFP-01). Immunohistochemistry (Paraffin): Heat mediated antigen retrieval (sodium citrate buffer); mAb incubation 1 hour / RT, detection DAB; Western Blot: non-reducing conditions.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

AFP-11

Vial size

100 µg

Concentration

1 mg/mL

Storage

4° C, do not freeze

References

Submitted references

Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction.

Lee-Montiel FT, Laemmle A, Charwat V, Dumont L, Lee CS, Huebsch N, Okochi H, Hancock MJ, Siemons B, Boggess SC, Goswami I, Miller EW, Willenbring H, Healy KE
Frontiers in pharmacology 2021;12:667010

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blotting analysis of human alpha-fetoprotein using mouse monoclonal antibody AFP-11 on lysates of HepG2 cell line and Jurkat cell line (negative control) under reducing and non-reducing conditions. Nitrocellulose membrane was probed with 2µg/mL of mouse monoclonal antibody anti-alpha-fetoprotein (Product # MA1-19342) followed by IRDye800-conjugated anti-mouse secondary antibody. Alpha-fetoprotein was detected at approximately 60kDa.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical analysis of AFP using a monoclonal antibody (Product # MA1-19342).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemistry staining of hepatocellular carcinoma (fetal liver; paraffin-embedded sections) with anti-human alpha-Fetoprotein (AFP-11) Monoclonal antibody (Product # MA1-19342).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIGURE 1 Differentiation and characterization of hiPSC-Heps. (A) Schematic of the hiPSC-Hep differentiation protocol. The arrows show cells at different stages progressing from hiPSCs (day 0) to mature hepatocytes (day 23). Growth factors and small molecules are listed inside the arrows. (B) Brightfield and immunofluorescent images matching the differentiation stages in (A) . Nuclei were stained with DAPI. Scale bars, 100 um. (C) Flow cytometry shows percentage of hiPSC-Heps expressing albumin and ASGR1 at day 23. (D) Activity analysis of uptake transporters by inhibition with specific inhibitors. Results obtained without inhibitors were set to 100% to display transporter activity as decrease of drug concentration in the cells. Data are presented as the mean +- standard deviation from three to four (hiPSC-Heps) or two to three (pHeps) independent experiments. (E) Activity analysis of efflux transporters by inhibition with specific inhibitors. Results obtained without inhibitors were set to 100% to display transporter activity as increase of drug concentration in the cells. Data are presented as the mean +- standard deviation from four to five (hiPSC-Heps) and three (pHeps) independent experiments. (F) Activity analysis of CYPs. Data are presented as the mean +- standard error of the mean from three (hiPSC-Heps) or two (pHeps) independent experiments. (G) Quantitative reverse transcription PCR analysis of CYP genes. (H) Activity analysis of conjugating enzymes. Data are presen